MindBio Therapeutics Advances to Phase 2B Clinical Trial in Major Depressive Disorder with MB22001

MindBio Therapeutics has initiated the Phase 2B clinical trial of its microdosing treatment, MB22001, for Major Depressive Disorder (MDD). This follows a successful Phase 2A trial which reported significant reductions in depressive symptoms. The trial is notable for allowing participants to self-administer MB22001, a form of Lysergic Acid Diethylamide (LSD), at home. The study encompasses a double-blind, randomised, placebo-controlled design with an open-label extension, aiming to collect data over 16 weeks from each participant.

The Phase 2B trial seeks to demonstrate the scalability of using sub-hallucinogenic doses of psychedelics for treating depressive disorders globally, aiming at a low side effect profile and improved adherence over traditional antidepressants. The CEO of MindBio, Justin Hanka, highlighted the trial's ambition to offer an accessible and affordable treatment without the drawbacks of current antidepressants. Previous trials of MB22001 have shown not only a reduction in depressive symptoms but also enhancements in sleep, mood, and general wellbeing.